These studies confirmed the anti-diabetic and anti-obesity effects of FGF-21 (Kharitonenkov et al., 2007; Coskun et al., 2008; Xu et al., 2009a), which further accelerated the clinical translation of FGF-21. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.